Yale Cancer Center | Strategic Alliance Partners

The Breast Cancer Research Foundation has awarded a 1-year, $175,000 research grant to Yale Cancer Center to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence.

James B. Yu, MD, MHS, has been promoted to Associate Chief Medical Officer for Radiation Oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network.

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

Markus Müschen, MD, PhD, has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital.

One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and sometimes be fatal.

Yale Cancer Center researchers were awarded a $2.8 million grant from the National Cancer Institute to evaluate and model cytokine signaling related to immunotherapy for cancer.

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.

Lajos Pusztai, MD, DPhil, discusses the results from the I-SPY 2 trial, as well as the clinical implications of the findings.

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Daniel P. Petrylak, MD, discusses the current treatment landscape of metastatic urothelial carcinoma and exciting strategies in the pipeline.

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Mario Sznol, MD, professor of medicine, co-director, Cancer Immunology Program, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses factors to consider when combining VEGF TKIs with immunotherapy in renal cell carcinoma (RCC).

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.